Highlights in breast cancer from the 2017 American Society of Clinical Oncology Annual Meeting.
نویسنده
چکیده
Treatment with T-DM1, either alone or in combination with pertuzumab (Perjeta, Genentech), produces noninferior progression-free survival (PFS) compared with the standard first-line treatment for HER2-positive metastatic breast cancer (trastuzumab and a taxane), according to primary results from the phase 3 MARIANNE study. The addition of pertuzumab to T-DM1 did not improve PFS. Although T-DM1 did not produce superior PFS, it was better tolerated than standard treatment, said Dr Paul Ellis of Guy’s Hospital and Sarah Cannon Research Center in London, the United Kingdom, who presented the results. For the study, researchers assigned 1095 women with HER2-positive, locally advanced or metastatic breast cancer to one of 3 groups: trastuzumab plus a taxane (docetaxel or paclitaxel), T-DM1 plus placebo, or T-DM1 plus pertuzumab. Randomization to placebo or pertuzumab was blinded. The median age of the patients was 52 to 55 years, 21% were premenopausal, and 66% to 71% had visceral metastases. Between 44% and 45% of the patients had received no prior neoadjuvant or adjuvant treatment, and approximately one-third had received adjuvant HER2directed treatment. After a median follow-up of 35 months, PFS was 13.7 months in the trastuzumab/taxane group, 14.1 months in the T-DM1/placebo group, and 15.2 months in the T-DM1/pertuzumab group. Both of the T-DM1–containing arms demonstrated noninferior PFS compared with the standard treatment arm, but did not Response Rates High for T-DM1 in HER2Positive/HR-Positive Early Breast Cancer
منابع مشابه
Highlights from the Gynecologic Oncology Track at the 2017 Annual Meeting of the American Society of Clinical Oncology
The American Society of Clinical Oncology (ASCO) 2017 Annual Meeting was held again at the McCormick Convention Center in Chicago, IL, USA. Over 37,500 international physicians, nurses, researchers, and exhibitors descended on the Windy City from June 2nd, 2017 through June 6th, 2017. This year's ASCO presidential theme, “Making a Difference in Cancer Care with You,” embodied the principle of t...
متن کاملHighlights in metastatic colorectal cancer from the 2012 American Society Of Clinical Oncology Annual Meeting.
متن کامل
ASCO 2017—highlights of gynecological cancer
At this year's ASCO annual meeting several important studies in the field of gynecological cancer were presented. Here we report a personal selection of the most interesting and clinically relevant data.
متن کاملAmerican society of clinical oncology, 45th annual meeting.
The 46th Annual Meeting of the American Society of Clinical Oncology, held in Chicago, included topics covering new therapeutic developments in the field of oncology. This conference report highlights selected presentations on novel therapies for cancers including glioblastoma, breast cancer, myeloma, NSCLC and solid tumors. Investigational drugs discussed include rindopepimut and PF-299804 (bo...
متن کاملEisai Oncology to Present New Research on Product Portfolio, Pipeline at Asco Annual Meeting
PIPELINE AT ASCO ANNUAL MEETING Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, “Eisai”) announced today that 19 abstracts highlighting new study results on thyroid cancer, acute myeloid leukemia, metastatic breast cancer, ovarian cancer and other cancers will be presented during the 47 Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Ch...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Clinical advances in hematology & oncology : H&O
دوره 13 7 شماره
صفحات -
تاریخ انتشار 2015